Population-level cascade of care for hepatitis C in Newfoundland and Labrador

Author:

Whitten Cindy123,Turner Alison1,Roberts Kobe2,Howell Brittany1,Sparkes Brooklyn1,Daley Peter12

Affiliation:

1. Newfoundland and Labrador Health Services, Memorial University of Newfoundland, St John's Newfoundland and Labrador, Canada

2. Memorial University of Newfoundland, St John's Newfoundland and Labrador, Canada

3. Correspondence: Cindy Whitten, Newfoundland and Labrador Health Services, St John's Newfoundland and Labrador, A1B 3V6 Canada.

Abstract

Background: Global elimination of hepatitis C virus (HCV) is feasible using existent tools. Reporting the provincial HCV care cascade will contribute to national and global HCV elimination efforts. Methods: This observational study was a secondary use of population-level medical record data, including laboratory results for HCV testing and prescription data for HCV treatment in the province of Newfoundland and Labrador (NL). All patients with HCV antibody testing performed between Jan 1, 2017 and Jan 1, 2022 were included. All prescriptions dispensed from a community pharmacy in NL for any HCV treatment during the same period were included. Results: There were 84,252 antibody tests included. Of these, 3,626 (4.3%) tests were positive for HCV antibodies. Seventy eight percent (1,377/1,766) of the individuals with positive antibody tests were tested for HCV RNA. Only 377/1,061 (35.5%) individuals with a positive RNA test were treated, and 257/395 (65.1%) achieved sustained virological response at 12 weeks. Conclusions: NL has successfully identified and treated HCV, but treatment access is low. Targets for improvement include increased screening, reflex testing of positive antibody with RNA, increased linkage to care, change in treatment funding policy, and quicker treatment funding decision.

Publisher

University of Toronto Press Inc. (UTPress)

Reference14 articles.

1. Public Health Agency of Canada. Reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2030: a Pan-Canadian STBBI Framework for Action; 2018. https://www.canada.ca/content/dam/phac-aspc/documents/services/infectious-diseases/sexual-health-sexually-transmitted-infections/reports-publications/sexually-transmitted-blood-borne-infections-action-framework/sexually-transmitted-blood-borne-infections-action-framework.pdf (accessed November 2022).

2. Action Hepatitis Canada. Progress towards viral hepatitis elimination by 2030 in Canada; 2021. https://www.actionhepatitiscanada.ca/progressreport (accessed November 2022).

3. The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination efforts in Canada; 2019. https://www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf (accessed November 2022).

4. Office of Infectious Disease and HIV/AIDS Policy (OIDP). Hepatitis C basics; 2022. https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/hepatitis-c-basics/index.html (accessed September, 2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3